Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual General Meeting of Shareholders held by ProKidney Corp. on May 30, 2024. The company is incorporated in the Cayman Islands and its Class A ordinary shares trade on The Nasdaq Stock Market under the symbol PROK.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Shareholders voted on two primary matters at the Annual General Meeting:
- Election of Directors: Shareholders elected two nominees to the Board of Directors for three-year terms expiring in 2027:
- Jennifer Fox: 180,074,590 votes For; 1,649,737 votes Against; 218 Abstain; 4,943,486 Broker Non-Votes.
- José Ignacio Jiménez Santos: 180,893,693 votes For; 830,587 votes Against; 265 Abstain; 4,943,486 Broker Non-Votes.
- Ratification of Auditors: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes: 182,470,555 For; 4,195,327 Against; 2,149 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the composition of the Board of Directors following the election of Jennifer Fox and José Ignacio Jiménez Santos.
- Confirm the engagement of Ernst & Young LLP for the 2023 fiscal year audit.
- Review the company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.